PeptideAuthority

Loading...

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-03

Share:X Post LinkedIn

Longevity & Anti-Ageing•Updated 2026-02-03•7 min read

What Is Leuphasyl? Benefits, Research & Safety

A 5-amino acid neuromuscular peptide that reduces expression lines through the enkephalin pathway, enhancing the effects of Argireline and SNAP-8.

Also known as:

Pentapeptide-18

INCI: Pentapeptide-18

Educational Content Only: This page provides research-based information for educational purposes. Leuphasyl is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.

Quick Facts

Category

Longevity & Anti-Ageing

Half-Life

Effects persist while product remains on skin; must be applied consistently for maintained benefits; effects are cumulative with regular use

UK Status

Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.

EU Status

Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.

Overview

Leuphasyl (pentapeptide-18) is a neuromuscular peptide developed by Lipotec as a complementary ingredient to their Argireline family. Unlike Argireline and SNAP-8 which target the SNARE complex, Leuphasyl works through the enkephalin pathway—modulating neurotransmitter release via opioid-like receptor activation. This distinct mechanism makes Leuphasyl particularly valuable as an enhancer for other neuromuscular peptides. When combined with Argireline or SNAP-8, Leuphasyl creates a dual-pathway approach to reducing expression lines, with studies suggesting the combination may be more effective than either peptide alone. Leuphasyl's sequence (Tyr-D-Ala-Gly-Phe-Leu) is modelled on the natural enkephalin peptides that regulate neurotransmission. By mimicking these endogenous signalling molecules, Leuphasyl reduces the intensity of nerve signals that trigger facial muscle contractions—the root cause of expression lines like crow's feet, forehead wrinkles, and frown lines. Developed in the mid-2000s, Leuphasyl is now featured in advanced multi-peptide anti-ageing formulations, often alongside Argireline and SNAP-8 for comprehensive neuromuscular wrinkle reduction. **Important Note:** Leuphasyl is a cosmetic ingredient for topical use. It is not a pharmaceutical and effects are subtle compared to injectable neurotoxins. This information is for educational purposes.

Discovery & History

Leuphasyl was developed by Lipotec Laboratories (Barcelona, Spain) as part of their expanding neuromuscular peptide portfolio following the commercial success of Argireline. The development strategy was to create a peptide that would work through a complementary mechanism, allowing enhanced results when combined with existing SNARE-targeting peptides. The design of Leuphasyl drew inspiration from the endogenous enkephalin peptides—naturally occurring opioid peptides that modulate neurotransmission throughout the nervous system. Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) are the primary enkephalins involved in pain modulation and neuromuscular regulation. Lipotec's researchers modified the enkephalin structure to create a cosmetically suitable peptide: - **Tyrosine (Tyr)** at position 1 for receptor binding - **D-Alanine** at position 2 for stability (the D-form resists enzymatic degradation) - **Glycine (Gly)** at position 3 for flexibility - **Phenylalanine (Phe)** at position 4 for receptor interaction - **Leucine (Leu)** at position 5 for signalling specificity This pentapeptide sequence activates enkephalin receptors on nerve terminals, reducing neurotransmitter release through a mechanism distinct from SNARE complex inhibition. The result is a complementary approach to reducing facial muscle contractions. Leuphasyl was positioned as an "enhancer" for Argireline rather than a replacement, with marketing focusing on the synergistic benefits of combining both peptides. This strategy proved successful, with many premium anti-ageing products now featuring the Argireline + Leuphasyl combination. Lipotec was acquired by Lubrizol in 2012, which continues to manufacture and market Leuphasyl as part of their neuromuscular peptide range alongside Argireline and SNAP-8.

Mechanism of Action

Leuphasyl exerts its wrinkle-reducing effects through the enkephalin pathway—a mechanism distinct from the SNARE complex inhibition of Argireline and SNAP-8: **Enkephalin Receptor Activation** Leuphasyl's sequence (Tyr-D-Ala-Gly-Phe-Leu) mimics natural enkephalin peptides, allowing it to bind to enkephalin receptors on peripheral nerve terminals in the skin. **Mechanism of Action:** 1. **Receptor Binding:** Leuphasyl binds to δ-opioid receptors (and possibly μ-opioid receptors) on nerve terminals 2. **Calcium Channel Modulation:** Receptor activation reduces calcium influx into nerve terminals 3. **Reduced Neurotransmitter Release:** Lower intracellular calcium decreases acetylcholine vesicle fusion and release 4. **Attenuated Muscle Contraction:** Less acetylcholine means weaker signals to facial muscles 5. **Expression Line Reduction:** Reduced muscle contraction intensity allows expression lines to soften **Comparison to SNARE-Targeting Peptides:** While Argireline and SNAP-8 interfere with the SNARE complex (the fusion machinery), Leuphasyl works upstream by reducing the calcium signal that triggers vesicle fusion. This creates two independent pathways to the same outcome: - **Argireline/SNAP-8:** Block the fusion mechanism → fewer vesicles release contents - **Leuphasyl:** Reduce the release signal → fewer vesicles attempt to fuse **Synergy with Argireline/SNAP-8:** When combined, these peptides create multiplicative rather than additive effects: - Two independent mechanisms targeting neurotransmitter release - Leuphasyl reduces the "trigger signal" while Argireline/SNAP-8 block the "release mechanism" - Studies suggest 25% enhanced efficacy when combined versus Argireline alone **No Systemic Opioid Effects:** Despite working through opioid receptors, Leuphasyl: - Acts locally on peripheral nerve terminals only - Does not cross the blood-brain barrier - Does not produce systemic opioid effects (no pain relief, sedation, or dependence) - Works at concentrations far below those needed for central effects **Reversible and Subtle:** Like other cosmetic peptides, Leuphasyl's effects are: - Fully reversible upon discontinuation - Subtle compared to injectable neurotoxins - Cumulative with consistent use - Safe for ongoing cosmetic application

[Molecular Structure Diagram Placeholder]

Researched Benefits

Based on preclinical and clinical research findings:

1
Reduces expression lines through enkephalin pathway (distinct from Argireline)
2
Enhances efficacy of Argireline/SNAP-8 when combined (synergistic effect)
3
Up to 25% improved wrinkle reduction versus Argireline alone in studies
4
Softens crow's feet, forehead lines, and frown lines
5
Dual-pathway approach provides comprehensive neuromuscular modulation
6
Excellent tolerability with rare side effects
7
Compatible with all skin types including sensitive skin
8
Suitable for use morning and evening
9
Works independently if used alone
10
No systemic opioid effects despite enkephalin receptor mechanism

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Typically used at 3-8% concentration in topical formulations; often combined with Argireline or SNAP-8 at similar concentrations
Frequency	Applied twice daily to expression-prone areas (forehead, crow's feet, frown lines)
Duration	Visible improvements typically begin within 2-4 weeks; optimal results at 8+ weeks of consistent use
Notes	Leuphasyl is most effective when combined with Argireline or SNAP-8 for dual-pathway neuromuscular modulation. Apply to clean, dry skin on areas with expression lines before heavier products. Can be used morning and evening. For comprehensive anti-ageing, add collagen-stimulating peptides like Matrixyl to address structural ageing alongside expression line reduction.

Administration Routes

Routes studied in research settings (educational only):

Topical application in serums (most common)
Topical application in multi-peptide anti-ageing formulations
Topical application in eye contour treatments
Topical application in targeted wrinkle treatments

Half-Life	Stability
Effects persist while product remains on skin; must be applied consistently for maintained benefits; effects are cumulative with regular use	Stable in properly formulated cosmetic products; the D-Alanine in position 2 provides enzymatic stability; should be stored in cool, dark conditions; typically 12-24 month shelf life

Safety Profile & Known Risks

Commonly Reported Side Effects

Very well tolerated—side effects are rare
Mild skin irritation possible in sensitive individuals (uncommon)
Temporary redness at application site (rare)
Slight tingling sensation on initial application (occasional)

Rare Risks & Concerns

Allergic reactions (very rare with peptides)
Eye irritation if product enters eyes
No systemic opioid effects at cosmetic concentrations

Contraindications

Known allergy to peptides or specific formulation components
Active skin infections at application site
Open wounds (use only on intact skin)

UK & EU Regulatory Context

🇬🇧 United Kingdom

Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.

🇪🇺 European Union

Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.

Leuphasyl (pentapeptide-18) is a fully approved cosmetic ingredient with established safety data. Despite working through enkephalin receptors, it has no opioid drug classification—effects are localised and cosmetic. Manufactured by Lubrizol (formerly Lipotec) and available globally in cosmetic formulations.

Clinical Studies Summary

Synergistic Efficacy with Argireline

Studies examining Leuphasyl combined with Argireline showed enhanced wrinkle reduction compared to Argireline alone—approximately 25% improvement. The dual-pathway approach (enkephalin + SNARE) provided superior results to single-mechanism treatments.

Lipotec Technical DocumentationView on PubMed

Expression Line Reduction Study

Clinical evaluation of Leuphasyl formulations demonstrated significant reduction in periorbital and forehead expression lines over 28 days of twice-daily application. Participants showed visible improvement in dynamic wrinkle severity.

Lipotec Clinical DataView on PubMed

Enkephalin Receptor Mechanism Studies

In vitro studies confirmed Leuphasyl's mechanism by demonstrating binding to enkephalin receptors and subsequent reduction in neurotransmitter release from nerve terminal models. The mechanism is distinct from SNARE complex inhibition.

Cosmetic Science ResearchView on PubMed

Dual-Pathway Combination Studies

Research on Leuphasyl + Argireline combinations demonstrated synergistic effects. The independent mechanisms (calcium channel modulation vs SNARE inhibition) work together to reduce muscle contraction through complementary pathways.

Lipotec Technical DataView on PubMed

Safety and Tolerability Assessment

Cumulative safety data from commercial use demonstrates excellent tolerability with no significant adverse events. No systemic opioid effects were observed despite the enkephalin receptor mechanism—effects are localised to application site.

Cosmetic Ingredient ReviewView on PubMed

Looking for Leuphasyl?

Source research-grade Leuphasyl from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Related Research Guides

Peptides for Skin Health

Peptides for Anti-Ageing

Peptides for Wrinkle Reduction

Peptide Comparisons

Leuphasyl vs Argireline

Compare peptides

Leuphasyl vs Syn-Ake

Compare peptides

Argireline vs Matrixyl

Compare peptides

SNAP-8 vs Argireline

Compare peptides

Leuphasyl vs SNAP-8

Compare peptides

Combination Protocols

GHK-Cu + Matrixyl + Argireline Anti-Ageing Stack

Argireline + Leuphasyl + SNAP-8 Neuromuscular Stack

Syn-Ake + Argireline + Leuphasyl Triple Neuromuscular Stack

Quad-Pathway Neuromuscular Stack

Related Peptides

GHK-Cu

A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.

Matrixyl

A pioneering signal peptide that mimics natural collagen-boosting messengers, extensively validated in clinical studies for wrinkle reduction and skin firmness improvement.

Argireline

A neuromodulating hexapeptide that reduces facial muscle contractions through SNARE complex inhibition, providing a topical alternative to botulinum toxin for expression line reduction.

SNAP-8

An enhanced 8-amino acid version of Argireline with improved penetration and efficacy for reducing expression lines through SNARE complex modulation.

Syn-Ake

A tripeptide that mimics the neuromuscular blocking effects of Temple Viper venom (waglerin-1), targeting nicotinic acetylcholine receptors to reduce expression lines.

Explore More Peptides

Browse our comprehensive database of research-backed peptide profiles.